Ausgabe 5/2019
Inhalt (13 Artikel)
Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?
Kelly George, Gillian Woollett
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine
Pavine L. C. Lefevre, Lisa M. Shackelton, Niels Vande Casteele
Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis
Soohyun Lee, Heeyoung Lee, EunYoung Kim
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Luke Russell, Kah Whye Peng, Stephen J. Russell, Rosa Maria Diaz
The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks
Arash Hajizadeh Dastjerdi, Anthony Newman, Gaetan Burgio
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Lorraine Springuel, Caroline Lonez, Bertrand Alexandre, Eric Van Cutsem, Jean-Pascal H. Machiels, Marc Van Den Eynde, Hans Prenen, Alain Hendlisz, Leila Shaza, Javier Carrasco, Jean-Luc Canon, Mateusz Opyrchal, Kunle Odunsi, Sylvie Rottey, David E. Gilham, Anne Flament, Frédéric F. Lehmann
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
Brittany L. Allen-Petersen, Rosalie C. Sears
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Niels Reinmuth, Maciej Bryl, Igor Bondarenko, Kostas Syrigos, Vladimir Vladimirov, Manuela Zereu, Angel H. Bair, Fiona Hilton, Katherine Liau, Kazuo Kasahara
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
Ellen Q. Wang, Jack F. Bukowski, Carla Yunis, Charles L. Shear, Paul M. Ridker, Pamela F. Schwartz, Daniel Baltrukonis
Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
Christopher J. Webster, Gillian R. Woollett
Comment on: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”
Isabel Puértolas-Tena, Alberto Frutos Pérez-Surio
Author’s Reply to Puértolas-Tena and Pérez-Surio: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”
Jichun Yang, Shuqing Yu, Zhirong Yang, Yusong Yan, Yao Chen, Hongmei Zeng, Fei Ma, Yanxia Shi, Yehui Shi, Zilu Zhang, Feng Sun
Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis
Jichun Yang, Shuqing Yu, Zhirong Yang, Yusong Yan, Yao Chen, Hongmei Zeng, Fei Ma, Yanxia Shi, Yehui Shi, Zilu Zhang, Feng Sun